

PADI4-mediated epithelial-mesenchymal transition in lung cancer cells

MEIYAN LIU¹, YANG QU², XUE TENG³, YING XING¹, DANDAN LI¹, CHUNHONG LI¹ and LI CAI¹

¹Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040;

²Department of Internal Medicine, The Second Hospital of Heilongjiang Province, Harbin, Heilongjiang 150010;

³Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China

Received June 5, 2018; Accepted February 14, 2019

DOI: 10.3892/mmr.2019.9968

Abstract. Lung cancer is a complex disease involving multiple genetic and phenotypic alterations. As a histone modification enzyme, protein-arginine deiminase type-4 (PADI4) and its downstream signaling have been studied in the progression of a variety of types of human cancer, but data on PADI4-mediated posttranslational modification in lung cancer are lacking. The aim of present study was to evaluate the expression of PADI4 and its associated molecular signaling in lung cancer metastasis. The results of the present study indicated that PADI4 was overexpressed in lung cancer cells, while knockdown of PADI4 could lead to attenuation of the lung cancer cell invasion and migration phenotype, which was further verified by determining the epithelial-mesenchymal transition (EMT) marker proteins. Additionally, it was demonstrated that stable knockdown of PADI4 in A549 lung cancer cells resulted in a striking reduction of the EMT-associated Snail1/mothers against decapentaplegic homolog 3/4 transcriptional complex, which was consistent with alterations in migratory and invasive phenotypes of A549 lung cancer cells. Therefore, PADI4-mediated EMT transition is proposed to represent a novel mechanism underlying the epigenetic and phenotypic alterations in lung cancer cells, and the PADI4 associated signaling pathway may be a therapeutic target for treating lung cancer in a clinical setting.

Introduction

Lung cancer is one of the most prevalent types of cancer worldwide with complex multiple genetic alterations (1,2). The

major obstacles to successful treatment of this carcinoma are recurrence and metastasis, which constitute a heavy medical burden and has become a serious human health challenge (3). Although several therapeutic strategies like targeted molecular therapy and immunotherapy for lung cancer have been developed in the past decades, the prognosis and survival rate for lung cancer patients are far from satisfactory (4,5). Therefore, it's urgent to investigate novel effective targets for the treatment of lung cancer.

Epithelial-mesenchymal transitions (EMT) are essential for carcinoma progression including initiation of metastasis (6,7). Therefore, investigation of EMT-associated signaling pathways is the focus of tumor metastasis research.

The progression of tumor metastasis is a complicated and multi-step process initiated by epithelial-to mesenchymal transition. In general, EMT is a pathophysiological process in which epithelial cells are transformed into a mesenchymal phenotypic cells through a series of gene expression regulatory actions (8). Numerous signaling pathways have been implicated in this process, including phosphatidyl 3 inositol kinase/protein kinase B, transforming growth factor- β , RAS and Wnt (9,10). In addition, several important downstream transcription factor targets have been identified, including Slug, mothers against decapentaplegic homolog (Smad), Twist and Snail (11,12), all of which have been reported to serve crucial roles in tumor invasion and metastasis.

Snail1, known as a negative regulatory zinc finger transcription factor, serves a key role in EMT during tumor progression by repressing extracellular junction components like epithelial (E)-cadherin (13,14). Commonly, Snail1 is thought to be activated by multiple factors and subsequently forms transcriptional repression complex with Smad3/4 (15). Based on this, the Snail1/Smad3/4 transcriptional complex is involved in the present study.

Protein arginine deiminase, type 4 (PADI4) is a calcium dependent enzyme which is known for its role in converting arginine to citrulline residues (16). Among its multitudinous downstream target proteins, the nuclear histone proteins are the best-described substrates to date. It has been reported that PADI4 is involved in the process of tumor development including proliferation, apoptosis and EMT (17-19). However, the biological function of PADI4 in lung cancer progression, particularly in the aspect of posttranslational modification of

Correspondence to: Professor Chunhong Li or Professor Li Cai, Department of Internal Medicine, Harbin Medical University Cancer Hospital, 6 Baojian Road, Nangang, Harbin, Heilongjiang 150040, P.R. China

E-mail: lichuanhong078@tom.com

E-mail: caili069@sohu.com

Key words: protein-arginine deiminase type-4, lung cancer, epithelial-mesenchymal transition, migration, invasion

transcription factor, is poorly understood. Therefore, sufficient knowledge of this histone modification enzyme may help to uncover the potential molecular mechanisms of lung tumor metastasis.

The documented involvement of transcription factors or enzymes in EMT prompted the present study to investigate whether PADI4 is involved in the signal pathway regulation network. In the present study, PADI4 was first identified, to the best of our knowledge, to serve crucial roles in the invasion and migration process of lung cancer cells. Evidence was provided that knockdown of PADI4 causes a dramatic decrease in lung cancer cell invasion and migration, which may be attributed to the interactions between PADI4 and EMT-associated transcription factors and enzymes. Collectively, the results of the present study demonstrate that PADI4 is necessary for maintaining a mesenchymal phenotype for lung cancer, which may become a novel target for the treatment of lung cancer in the future.

Materials and methods

Tissue samples. A total of 56 lung carcinoma tissues samples and their paired non-tumorigenic tissues samples were obtained between July 2016 to March 2017 from patients in the Harbin Medical University Cancer Hospital, (Harbin, China). They were 38 males and 18 females with an average age of 49 years. All these lung cancer patients were treatment-naïve prior to surgery and this study was approved by the ethical committee of the Harbin Medical University Cancer Hospital and written informed consent was obtained from every recruited patient.

Cell culture. Lung cancer cell lines A549, H1299 and normal lung epithelial cell line BEAS-2B were purchased from the Chinese Academy of Medical Sciences Cell Bank (Beijing, China). Cells were cultured in 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 12% fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, Logan, UT, USA) at 37°C in a humidified atmosphere containing 5% CO₂.

Cell transfection. The A549 cells were cultured in a 6-well plate at the appropriate cell density (~50%) for transfection. Knockdown of PADI4 was achieved by transfecting A549 cells with a short hairpin (sh)RNA-PADI4 (pSUPER-PADI4-shRNA, 5'-CAGGAGGTGTACGCGTGCAGTATTT-3') plasmid (1 µg/well) by Lipofectamine® 2000 (11668027; Invitrogen; Thermo Fisher Scientific, Inc.), which was purchased from Shanghai GenePharma Co., Ltd., (Shanghai, China), while a plasmid with a scramble sequence (5'-TTCTCCGAACGTGTCACGT-3') served as the negative control. After 24 h, the transfected cells were further processed for the following experiments.

Wound-healing assay. Briefly, 1x10⁵ BEAS-2B, H1299 and A549 cells in different groups were seeded in multi-well plates and cultured until confluent. The monolayers were then scraped off with a sterile pipette tip to create a gap. An image of cell migration was recorded at 0 and 24 h using a light microscope (Nikon Corporation, Tokyo Japan).

Transwell assay. To detect the invasive ability of lung cancer cells, Transwell plate chambers (8 µM pore size) coated with Matrigel (BD Biosciences; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) were used. First, BEAS-2B, H1299 and A549 cells (1x10⁴) were seeded in the upper chamber with serum-free medium, while complete medium (1640 medium with 15% FBS) was added to the bottom wells of the chambers. All Transwell chambers were incubated at 37°C and 5% CO₂ in culture medium. Following 24 h, the cells that had not migrated to the other side of the membrane were removed from the upper face of the filters, while the remaining cells were fixed with 95% ethanol for 15 min at room temperature and washed in tap water. Crystal violet solution (4 g/l) was added to each chamber for 10 min at room temperature; after which the chambers were washed again in tap water. Cells were then counted in five randomly chosen visual fields (magnification, x200) using a light microscope (Nikon Corporation) and the average value was calculated.

RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from BEAS-2B, H1299 and A549 cell lines using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. cDNA was synthesized from total RNA (1,000 ng) using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the temperature protocol of 25°C for 10 min, 37°C for 120 min and 85°C for 5 min. qPCR was performed using the SYBR Master Mix (Roche Diagnostics, Basel, Switzerland). All the primers were designed and synthesized by the Sangon Biotech Co., Ltd., (Shanghai, China). The primer sequences were as follows: PADI4 forward: 5'-CACAGCTCTGGTTGGCTTCA-3', reverse: 5'-CTGCACGTCCTTCAGCATCA-3'; GAPDH forward: 5'-CGGAGTCAACGGATTTGGTCGTAT-3', reverse: 5'-AGCCTTCTCCATGGTGGTGAAGAC-3'. The assays were performed on the 7500 Fast Real-Time PCR System (Applied Biosystem; Thermo Fisher Scientific, Inc.). The quantitative RT-PCR thermal cycling conditions included one cycle for 60 sec at 95°C and 40 cycles of 15 sec at 95°C, 15 sec at 60°C and 45 sec at 72°C. The results were calculated using the $\Delta\Delta$ quantification cycle (Cq) method (20) and then normalized to the endogenous reference control gene GAPDH.

Western blot assay. Briefly, total protein was extracted from lung cancer cells and normal lung epithelial cells, lung cancer tissues and paracancerous tissues. For detecting the transcription factors, nuclear protein was extracted using a Nuclear protein extraction kit (cat. no. R0050; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Protein samples (50 µg) were loaded and separated by 10% SDS-PAGE and then transferred to a 0.45 µm polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA; IPVH00010). The membranes were incubated with corresponding primary antibodies at 4°C overnight: PADI4 (cat. no. ab128086; 1:1,000; Abcam, Cambridge, UK), epithelial (E)-Cadherin (cat. no. 14472; 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), neural (N)-Cadherin (cat. no. 13116; 1:1,000; Cell Signaling Technology, Inc.), Vimentin (cat. no. 5741; 1:1,000; Cell Signaling Technology, Inc.), Smad3 (cat. no. 9523; 1:1,000; Cell Signaling Technology, Inc.), Smad4




Figure 1. The expression level of PADI4 in lung cancer tissues and paired non-tumoral tissues. (A) The expression of PADI4 was detected by immunohistochemistry in lung cancer tissues and paired non-tumoral tissues. (B) The expression of PADI4 was detected by western blotting in lung cancer tissues and paired non-tumoral tissues and the statistical analysis is presented. * $P < 0.05$ and ** $P < 0.01$ vs. Normal by two-tailed Student's t-test, $n = 3$. PADI4, protein-arginine deiminase type-4.

(cat. no. 46535; 1:1,000; Cell Signaling Technology, Inc.), Snail 1 (cat. no. 14-9859-82; 1:1,000; eBioscience; Thermo Fisher Scientific, Inc.), β -actin (cat. no. 3700; 1:1,000; Cell Signaling Technology, Inc.) and Histone H3 (cat. no. 4499; 1:1,000; Cell Signaling Technology, Inc.). After that, the membranes were washed with PBS-Tween-20 (0.05%) three times and subsequently incubated with secondary antibodies (cat. no. A32730 and cat. no. A32732, 1:2,000; Alexa Fluor; Thermo Fisher Scientific, Inc.) for 1 h at room temperature. Finally, the bands were detected by an Imaging System (LI-COR Biosciences, Lincoln, NE, USA) and quantified with the Odyssey v1.2 software (LI-COR Biosciences, Lincoln, NE, USA) by measuring intensity. For protein normalization, β -actin was used as the internal control.

Immunohistochemistry. Immunohistochemistry was performed to determine the expression level of PADI4 in lung cancer and corresponding paracancerous tissues. Briefly, consecutive 0.4 μ m sections were cut from each paraffin-embedded tissue and the slides were incubated overnight at 4°C with the PADI4 antibody (cat. no. ab128086; 1:1,000; Abcam, Cambridge, UK). After washing with PBS, the slides were incubated with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (Beyotime Institute of Biotechnology, Shanghai, China; cat. no. A0216, 1:500) for 30 min at 37°C. Afterwards, immunocomplexes were detected using the DAB Horseradish Peroxidase Color Development kit (Beyotime Institute of Biotechnology, cat. no. P0203). The slides were then counterstained with hematoxylin for 10 min at room temperature and mounted for examination under the light microscope (Olympus Corporation, Tokyo, Japan).

Statistical analysis. In each experiment, all determinations were performed at least in triplicate. All of the experimental data, which were analyzed with the Graphpad Prism v6.0 software (GraphPad Software, Inc., La Jolla, CA, USA), are represented as the mean \pm standard error of the mean.

One-way analysis of variance followed by Bonferroni's multiple comparison test was used to compare the differences between multiple groups. The Student's two-tailed t-test was used to determine the difference between two groups. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

PADI4 is upregulated in lung cancer tissues. To determine the possible clinical relevance of PADI4 in lung cancer, an immunohistochemistry assay and western blot analysis were performed. As presented in Fig. 1A, the expression of PADI4 in lung cancer samples was increased compared with in their corresponding normal tissues, which was further confirmed by the results of western blotting in Fig. 1B which demonstrated that the change was significant ($P < 0.05$).

The migration and invasion ability of lung cancer cells and normal lung epithelial cells. In the present study, the wound-healing assay and Transwell assay was first performed to determine and compare the migration and invasion ability of two lung cancer cell lines (H1299 and A549) and one normal lung epithelial cell line BEAS-2B. The results in Fig. 2A and B demonstrated that the ability of lung cancer cell lines (H1299 and A549) to migrate and invade is significantly increased compared with the normal lung epithelial cell line BEAS-2B ($P < 0.05$), while an even more pronounced potential was observed in A549 cells compared with H1299 cells.

The expression of PADI4 in vitro and knockdown of PADI4 in A549 cells. To investigate whether histone modification enzyme PADI4 is involved in the process of migration and invasion, the expression level of PADI4 in H1299, A549 and BEAS-2B cell lines was analyzed. It was observed that the mRNA and protein expression levels of PADI4 were significantly elevated in the H1299 and A549 lung cancer cell lines, compared with that in BEAS-2B normal lung epithelial cell




Figure 2. The migration and invasion features of lung cancer cells and normal lung epithelial cells. (A) The migration ability of H1299 and A549 cells, and BEAS-2B cells determined by wound-healing assay (magnification, $\times 200$) and the statistical results are presented. (B) The invasion ability of H1299, A549 and BEAS-2B cells determined by Transwell assay (magnification, $\times 400$) and the statistical analysis is presented. Differences between groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. * $P < 0.05$ or ** $P < 0.01$ vs. BEAS-2B; # $P < 0.05$ vs. H1299, $n = 3$.

line ($P < 0.05$; Fig. 3A and B). Since the PADI4 protein level exhibited a greater increase in A549 cells than that in H1299 cells, A549 cells were chosen for the following molecular mechanism investigation.

Using plasmids carrying shRNA (pSUPER-PADI4-shRNA) targeting PADI4, the expression of PADI4 in A549 cells was knocked down. The knockdown efficiency was confirmed by the RT-qPCR and western blot assay, as presented in Fig. 3C and D.

Knockdown of PADI4 decreases the migratory and invasive potential of A549 cells. To verify whether the knockdown of PADI4 could induce phenotypic alterations in A549 cells, wound-healing assay and Transwell assay were conducted to detect the motility and invasiveness of A549 cells. The data suggested that knockdown of PADI4 significantly attenuated the migratory phenotype of A549 cells in the wound-healing assay. Similarly, the results of the Transwell assay demonstrated that the invasive ability of shPADI4 A549 was significantly reduced compared with the control group ($P < 0.05$; Fig. 4A and B). The above results indicated that PADI4 served a beneficial role in the cell motility and invasiveness phenotypic type, but the underlying mechanisms need to be further investigated.

PADI4 is involved in the EMT-associated signaling pathway. EMT entails profound epigenetic and phenotypic modifications to a cell. Previous studies have reported that epithelial

cells express high levels of E-cadherin, whereas mesenchymal cells express high levels of N-cadherin and vimentin (21-23). Therefore, detecting the expression level of E-cadherin, N-cadherin and vimentin has become a prevalent strategy for the verification of EMT in cells. Fig. 5A and B demonstrated that the epithelial markers E-cadherin was significantly increased in shPADI4 A549 cells, while the mesenchymal markers N-cadherin and vimentin were significantly decreased ($P < 0.05$). These data fit well with the authors' hypothesis that PADI4 was involved in the EMT-associated phenotypic alterations.

Additionally, to determine the involvement of EMT-associated transcription factors in the PADI4-mediated alterations in tumor characteristics, the expression of the Snail1/Smad3/4 transcriptional complex was also analyzed in the A549 lung cancer cells. Consistent with the prominent alterations in EMT-associated marker proteins, the expression levels of Snail1/Smad3/4 were significantly reduced in shPADI4 A549 cells, compared with the cells in the control group ($P < 0.05$; Fig. 5C and D). This evidence demonstrated that PADI4 exerted crucial roles in the process of EMT, which partially controlled the EMT-associated transcription factors and subsequently transforming the cell epigenetic, and phenotypic types.

Discussion

Previous studies have pointed to PADI4 as a novel candidate molecule to be incorporated into the epigenetic and phenotypic




Figure 3. The expression levels of PADI4 *in vitro* and knockdown of PADI4 in A549 cells. (A) The statistical analysis represents the mRNA expression level of PADI4 in different lung cancer cells and normal lung epithelial cells. (B) The representative bands of western blotting and the statistical analysis. Differences among groups were analyzed by one-way ANOVA, followed by Bonferroni's multiple comparison test. * $P < 0.05$ or ** $P < 0.01$ vs. BEAS-2B, # $P < 0.05$ vs. H1299, $n = 3$. (C) The efficiency of PADI4 knockdown by shRNA was confirmed by reverse transcription-quantitative polymerase chain reaction. (D) The efficiency of PADI4 knockdown by shRNA was confirmed by western blotting. Differences among groups were analyzed by one-way ANOVA, followed by Bonferroni's multiple comparison test. ** $P < 0.01$ vs. Ctrl, $n = 3$. Ctrl, control; NC, negative control; sh, short hairpin; PADI4, protein-arginine deiminase type-4; ANOVA, analysis of variance.

alterations in a variety of carcinomas (24-26). However, the role of PADI4 and the downstream signaling pathway involved in cancer progression have not been investigated in lung cancer to date. In the present study evidence was provided that histone modification enzyme PADI4 and its potential downstream targets, may be key modulatory factors in lung cancer metastasis. The migratory and invasive phenotypes of lung cancer cells may be attributed to the increased expression level of PADI4.

To further evaluate the role of PADI4 in lung cancer progression, experimental cell models were generated with stable knockdown of PADI4 in A549 lung cancer cell line. Interestingly, the present data demonstrated that the stable knockdown of PADI4 led to phenotypic alteration defined as EMT. Consistent with A549 cells undergoing EMT, the present study's results also demonstrate that knockdown of PADI4 attenuated the migratory and invasive potential in A549 lung cancer cells, which were demonstrated by the wound-healing assay and Transwell assay. These data fit well with a previous study demonstrating that PADI4 may be a valid cancer susceptibility gene that accounted for gastric cancer invasion (26).

Additionally, in order to identify potential target substrates of PADI4 that may account for the induction of EMT in A549 cells, the expression levels of EMT-associated transcription factors and identified Snail1/Smad3/4 as potential targets of PADI4 were measured. Since previous studies have confirmed that Snail1/Smad3/4 transcriptional complex is a potent promoter of EMT (15,19), it is necessary to clarify the association between the expression level of Snail1/Smad3/4 and PADI4. The results of the present study indicated that knockdown of PADI4 significantly reduced the expression levels of Snail1/Smad3/4, which further confirmed the strong correlation between PADI4 and EMT transcription factors. However, how PADI4 affects the expression of EMT-associated transcription factors requires further experimental verification.

In addition, it is worth noting that Stadler *et al* (18) have demonstrated that PADI4 serves a critical role in maintaining an epithelial phenotype in breast cancer, which is contrary to the present study. However, according to previous literature searches, the same gene may serve different roles in different types of cancer (27,28). A previous study has also demonstrated that PADI4 is highly expressed in various malignancies (29),




Figure 4. Knockdown of PADI4 inhibits the migration and invasion ability of A549 cell. (A) The migration potential of A549 cells and shPADI4 A549 cells determined by wound-healing assay (magnification, x200) and the statistical results are presented. (B) The invasion potential of A549 cells and shPADI4 A549 cells assessed by Transwell assay (magnification, x400) and the statistical chart. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. * $P < 0.05$ vs. Ctrl, $n = 3$. sh, short hairpin; PADI4, protein-arginine deiminase type-4; Ctrl, control; NC, negative control.




Figure 5. PADI4 was involved in the process of EMT. (A) Knockdown of PADI4 increased the expression of epithelial makers (E-cadherin) and reduced the expression of mesenchymal markers (N-cadherin and vimentin). (B) The statistical chart represents the relative protein expression levels. (C) Knockdown of PADI4 reduced the EMT-associated Snail1/Smad3/4 transcriptional factors compared with the control group. (D) The statistical analysis represents the relative protein expression levels. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni's multiple comparison test. * $P < 0.05$ or ** $P < 0.01$ vs. control, $n = 3$. N, neural; E, epithelial; EMT, epithelial-mesenchymal transition; PADI4, protein-arginine deiminase type-4; Smad, mothers against decapentaplegic homolog; Ctrl, control; NC, negative control.

which suggests that PADI4 is a cancer-promoting gene in certain tumors. In addition, the data from Oncomine database (<https://www.oncomine.org/resource/login.html>) also provided evidence that the expression of PADI4 varies widely in different tumors (data not shown).

However, there are certain limitations in the present study. On one hand, it's unknown how PADI4 regulates its downstream target in lung cancer. On the other hand, it's not clear whether there are other important molecules or enzymes including GSK3 β involved in PADI4-mediated phenotypic changes in lung cancer, which needed to be developed in the future. In conclusion, in the present study it has been demonstrated that PADI4 was overexpressed in lung cancer tissues and lung cancer cell lines (A549 and H1299), which closely associated with EMT and cell migration and invasion phenotypes, suggesting PADI4 may serve as a biomarker for evaluating the efficacy of therapy and prognosis of lung cancer in clinical practice. However, other molecules or enzymes may also be involved in the PADI4-mediated EMT phenotypic changes and future studies should be aimed at addressing the direct or indirect regulatory association between PADI4 and EMT-related transcription factors.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Haiyan Foundation from Harbin Medical University Cancer Hospital (grant nos. JJQN2014-02 and JJQN2014-04); National Health and Family Planning Commission of Heilongjiang Province (grant no. 2017-123); Department of Health of Heilongjiang province (grant no. 2014-352).

Availability of data and materials

The data and graphs used in the present study are available from the corresponding authors on reasonable request.

Authors' contributions

ML was mainly responsible for the design of this study. YQ, XT, YX and DL participated in all the experiments including western blotting, RT-qPCR, and Transwell assay. LC and CL were the mentors for the subjects and mainly responsible for the study design and revision of this manuscript.

Ethics approval and consent to participate

The present study was approved by the ethical committee of the Harbin Medical University Cancer Hospital and the written informed consent to participate was obtained from every recruited patient.

Patient consent for publication

All of the recruited patients agree to the publication of this article.

Competing interests

The authors declare that they had no competing interests.

References

1. Weeden CE, Ah-Cann C, Holik AZ, Pasquet J, Garnier JM, Merino D, Lessene G and Asselin-Labat ML: Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. *Oncogene* 37: 4475-4488, 2018.
2. Devarakonda S, Morgensztern D and Govindan R: Genomic alterations in lung adenocarcinoma. *Lancet Oncol* 16: e342-e351, 2015.
3. Zhang D, Chen Z, Wang DC and Wang X: Regulatory T cells and potential immunotherapeutic targets in lung cancer. *Cancer Metastasis Rev* 34: 277-290, 2015.
4. Zhang W, Fan J, Chen Q, Lei C, Qiao B and Liu Q: SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma. *Oncol Lett* 15: 7028-7036, 2018.
5. Wang PS, Chou CH, Lin CH, Yao YC, Cheng HC, Li HY, Chuang YC, Yang CN, Ger LP, Chen YC, *et al*: A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. *Oncogene* 37: 4662-4678, 2018.
6. Nourri M, Ratther E, Stylianou N, Nelson CC, Hollier BG and Williams ED: Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: An opportunity for intervention. *Front Oncol* 4: 370, 2014.
7. Ingthorsson S, Andersen K, Hilmarsdottir B, Maeldandsmo GM, Magnusson MK and Gudjonsson T: HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. *Oncogene* 35: 4244-4255, 2016.
8. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 7: 131-142, 2006.
9. Zhao Z, Liu H, Hou J, Li T, Du X, Zhao X, Xu W, Xu W and Chang J: Tumor Protein D52 (TPD52) inhibits growth and metastasis in renal cell carcinoma cells through the PI3K/Akt signaling pathway. *Oncol Res* 25: 773-779, 2017.
10. Chen H, Yang T, Wang MC, Chen DQ, Yang Y and Zhao YY: Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF- β -mediated Smad3 phosphorylation. *Phytomedicine* 42: 207-218, 2018.
11. Kim TW, Lee SY, Kim M, Cheon C, Jang BH, Shin YC and Ko SG: DSGOST regulates resistance via activation of autophagy in gastric cancer. *Cell Death Dis* 9: 649, 2018.
12. Liang W, Lai Y, Zhu M, Huang S, Feng W and Gu X: Combretastatin A4 regulates proliferation, migration, invasion, and apoptosis of thyroid cancer cells via PI3K/Akt signaling pathway. *Med Sci Monit* 22: 4911-4917, 2016.
13. Li X, Chen H, Liu Z, Ye Z, Gou S and Wang C: Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathway. *Cancer Lett* 431: 96-104, 2018.
14. Wang X, He J, Zhao X, Qi T, Zhang T and Kong C: Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells. *Oncol Rep* 39: 1835-1842, 2018.
15. Wang H, Chen Y and Wu G: SDHB deficiency promotes TGF β -mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4. *Transl Oncol* 9: 512-520, 2016.
16. Zhai Q, Wang L, Zhao P and Li T: Role of citrullination modification catalyzed by peptidylarginine deiminase 4 in gene transcriptional regulation. *Acta Biochim Biophys Sin (Shanghai)* 49: 567-572, 2017.
17. Tanikawa C, Espinosa M, Suzuki A, Masuda K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y and Matsuda K: Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. *Nat Commun* 3: 676, 2012.
18. Stadler SC, Vincent CT, Fedorov VD, Patsialou A, Cherrington BD, Wakshlag JJ, Mohanan S, Zee BM, Zhang X, Garcia BA, *et al*: Dysregulation of PADI4-mediated citrullination of nuclear GSK3 β activates TGF- β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. *Proc Natl Acad Sci USA* 110: 11851-11856, 2013.

19. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, *et al*: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. *Nat Cell Biol* 11: 943-950, 2009.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
21. Tsoukalas N, Aravantinou-Fatorou E, Tolia M, Giaginis C, Galanopoulos M, Kiakou M, Kostakis ID, Dana E, Vamvakaris I, Korogiannos A, *et al*: Epithelial-mesenchymal transition in non small-cell lung cancer. *Anticancer Res* 37: 1773-1778, 2017.
22. Xu YF, Ge FJ, Han B, Yang XQ, Su H, Zhao AC, Zhao MH, Yang YB and Yang J: High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma. *World J Gastroenterol* 21: 3256-3265, 2015.
23. Wang Y, Wu N, Sun D, Sun H, Tong D, Liu D, Pang B, Li S, Wei J, Dai J, *et al*: NUBPL, a novel metastasis-related gene, promotes colorectal carcinoma cell motility by inducing epithelial-mesenchymal transition. *Cancer Sci* 108: 1169-1176, 2017.
24. Kolodziej S, Kuvardina ON, Oellerich T, Herglotz J, Backert I, Kohrs N, Buscató EI, Wittmann SK, Salinas-Riester G, Bonig H, *et al*: PADI4 acts as a coactivator of Tall by counter-acting repressive histone arginine methylation. *Nat Commun* 5: 3995, 2014.
25. Christophorou MA, Castelo-Branco G, Halley-Stott RP, Oliveira CS, Loos R, Radziszewska A, Mowen KA, Bertone P, Silva JC, Zernicka-Goetz M, *et al*: Citrullination regulates pluripotency and histone H1 binding to chromatin. *Nature* 507: 104-108, 2014.
26. Xin J and Song X: Role of peptidylarginine deiminase type 4 in gastric cancer. *Exp Ther Med* 12: 3155-3160, 2016.
27. Wang L, Chang X, Yuan G, Zhao Y and Wang P: Expression of peptidylarginine deiminase type 4 in ovarian tumors. *Int J Biol Sci* 6: 454-464, 2010.
28. Sack LM, Davoli T, Li MZ, Li Y, Xu Q, Naxerova K, Wooten EC, Bernardi RJ, Martin TD, Chen T, *et al*: Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns. *Cell* 173: 499-514 e23, 2018.
29. Chang X and Fang K: PADI4 and tumorigenesis. *Cancer Cell Int* 10: 7, 2010.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

RETRACTED